Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
Vale SA
VALE
KB Home
KBH
Apple
AAPL
US Stock MarketDetailed Quotes
ENTA Enanta Pharmaceuticals
- 7.140
- -0.360-4.80%
Close Feb 14 16:00 ET
- 7.140
- 0.0000.00%
Post 20:01 ET
152.31MMarket Cap-1.44P/E (TTM)
7.680High7.080Low419.30KVolume7.500Open7.500Pre Close3.07MTurnover2.80%Turnover RatioLossP/E (Static)21.33MShares17.80052wk High1.36P/B107.10MFloat Cap4.71052wk Low--Dividend TTM15.00MShs Float127.770Historical High--Div YieldTTM8.00%Amplitude4.710Historical Low7.310Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Enanta Pharmaceuticals Stock Forum
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
Monday, 10th February at 4:01 pm
• On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025
• Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421
• On Track to Announce STAT6 Development Candidate in 2H 2025
• Operatio...
do you put much effort in the market to be early? I spend 10-16 hrs a day own (3) businesses and have a wife / (4) sons and a life but one is what they eat and i eat success and i win all the time…. find follow join and win connect to my efforts and win with me …..
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
• Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2
• Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified ...
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Positive
Achieved primary endpoint with 1.4 log viral load decline at Day 5 in Part 2
Demonstrated favorable safety profile with no treatment discontinuations
Received FDA Fast Track designation
Successfully achieved target drug exposure levels across all age groups
Showed 1.2 log viral loa...
• $A.O. Smith (AOS.US)$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum (CPE.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet (DNB.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
• $Enanta Pharmaceuticals (ENTA.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning (GLW.US)$ : CFRA Upgrades to Strong Buy ...
No comment yet